Peer-influenced content. Sources you trust. No registration required. This is HCN.

HealioFDA Warns of Oral Health Problems Linked to Transmucosal Buprenorphine

The FDA has issued a warning that transmucosal buprenorphine products may cause tooth decay, cavities, oral infections, and tooth loss. The federal agency said it has identified 305 cases of dental problems that were associated with buprenorphine tablets and films that dissolve under the tongue or against the inside of the cheek.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form